Merit Medical Executed An Asset Purchase Agreement With EndoGastric Solutions For A Total Cash Consideration Of ~$105M; Updates FY24 Financial Guidance EPS From $3.28-$3.35 To 3.22-$3.31 Vs $3.33 Est.; Revenue From $1.31B-$1.325B To $1.32B-$1.34B Vs...
Merit Medical Executed An Asset Purchase Agreement With EndoGastric Solutions For A Total Cash Consideration Of ~$105M; Updates FY24 Financial Guidance EPS From $3.28-$3.35 To 3.22-$3.31 Vs $3.33 Est.; Revenue From $1.31B-$1.325B To $1.32B-$1.34B Vs...
美適醫療與EndoGastric Solutions簽署了一項價值約1.05億美元的資產購買協議；更新FY24財務指引，每股收益從3.28-3.35美元調整爲3.22-3.31美元，預估爲3.33美元；營業收入從13.1-13.25億美元調整爲13.2-13.4億美元。
Merit Medical Executed An Asset Purchase Agreement With EndoGastric Solutions For A Total Cash Consideration Of ~$105M; Updates FY24 Financial Guidance EPS From $3.28-$3.35 To 3.22-$3.31 Vs $3.33 Est.; Revenue From $1.31B-$1.325B To $1.32B-$1.34B Vs $1.32B Est.
Merit Medical與EndoGastric Solutions簽署資產購買協議，總現金對價約1.05億美元；更新2024財年的財務指引，將每股收益從3.28-3.35美元調整至3.22-3.31美元，而市場預期爲3.33美元；營業收入從13.1億美元至13.25億美元調整至13.2億美元-13.4億美元，市場預期爲13.2億美元。
Asset acquisition expands Merit's endoscopy portfolio with a minimally invasive solution for patients suffering from chronic gastroesophageal reflux disease (GERD).
Asset acquisition projected to add approximately $30 million of revenue, on an annualized basis, in key gastrointestinal endoscopy market that leverages existing commercial footprint.
Merit reaffirms full-year 2024 financial guidance on standalone basis and updates full-year 2024 financial guidance to include projected partial-year impact from this acquisition.
資產收購擴大了Merit的內窺鏡組合，爲患有慢性胃食管反流病（GERD）的患者提供了微創解決方案。
通過現有的商業足跡，在關鍵的胃腸內窺鏡市場上預計資產收購將每年增加約3000萬美元的營業收入。
Merit在獨立經營指導下重申全年2024年財務指引，並更新全年2024年財務指引以包括預計本次資產收購的部分年度影響。
SOUTH JORDAN, Utah...
202...
登入免費觀看全文
登入/註冊